SERENA-1: Results from a Phase 1 Study (parts I/J) Testing the Next-Generation Oral Selective Estrogen Receptor Degrader (SERD) Camizestrant (AZD9833) in Combination with Capivasertib in Women with ER+, HER2 Advanced Breast Cancer
CANCER RESEARCH（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined